Drug Profile
C 3578
Alternative Names: C-3578Latest Information Update: 31 Jan 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 15 Dec 2005 Discontinued - Phase-II for Osteoporosis in USA (unspecified route)
- 31 Aug 2005 Phase-II clinical trials in Osteoporosis in USA (unspecified route)
- 07 Feb 2005 Phase-I clinical trials in Osteoporosis in USA (unspecified route)